JP7500438B2 - Egfr変異に関連する癌の治療組成物及び治療方法 - Google Patents

Egfr変異に関連する癌の治療組成物及び治療方法 Download PDF

Info

Publication number
JP7500438B2
JP7500438B2 JP2020567029A JP2020567029A JP7500438B2 JP 7500438 B2 JP7500438 B2 JP 7500438B2 JP 2020567029 A JP2020567029 A JP 2020567029A JP 2020567029 A JP2020567029 A JP 2020567029A JP 7500438 B2 JP7500438 B2 JP 7500438B2
Authority
JP
Japan
Prior art keywords
hours
plinabulin
minutes
tumor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525768A (ja
JP2021525768A5 (cg-RX-API-DMAC7.html
Inventor
ファン,ラン
ケネス ロイド,ジョージ
Original Assignee
ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド
Publication of JP2021525768A publication Critical patent/JP2021525768A/ja
Publication of JP2021525768A5 publication Critical patent/JP2021525768A5/ja
Application granted granted Critical
Publication of JP7500438B2 publication Critical patent/JP7500438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020567029A 2018-06-01 2019-05-30 Egfr変異に関連する癌の治療組成物及び治療方法 Active JP7500438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
US62/679,619 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (3)

Publication Number Publication Date
JP2021525768A JP2021525768A (ja) 2021-09-27
JP2021525768A5 JP2021525768A5 (cg-RX-API-DMAC7.html) 2022-06-06
JP7500438B2 true JP7500438B2 (ja) 2024-06-17

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567029A Active JP7500438B2 (ja) 2018-06-01 2019-05-30 Egfr変異に関連する癌の治療組成物及び治療方法

Country Status (11)

Country Link
US (2) US20210161888A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801524B1 (cg-RX-API-DMAC7.html)
JP (1) JP7500438B2 (cg-RX-API-DMAC7.html)
KR (1) KR102790127B1 (cg-RX-API-DMAC7.html)
CN (1) CN112543636B (cg-RX-API-DMAC7.html)
AU (1) AU2019278886B2 (cg-RX-API-DMAC7.html)
CA (1) CA3101612A1 (cg-RX-API-DMAC7.html)
DK (1) DK3801524T3 (cg-RX-API-DMAC7.html)
ES (1) ES3060133T3 (cg-RX-API-DMAC7.html)
MX (1) MX420412B (cg-RX-API-DMAC7.html)
WO (1) WO2019232257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN121311228A (zh) * 2023-06-02 2026-01-09 万春药业公司 肿瘤联合治疗和使用方法
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508167A (ja) 2011-03-14 2014-04-03 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
JP2018508572A (ja) 2015-02-12 2018-03-29 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 免疫チェックポイント阻害薬と併用するプリナブリンの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EA201200486A1 (ru) * 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
HK1249052A1 (zh) * 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals, Inc. composições de plinabulina e seu uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508167A (ja) 2011-03-14 2014-04-03 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
JP2018508572A (ja) 2015-02-12 2018-03-29 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 免疫チェックポイント阻害薬と併用するプリナブリンの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Heist, Rebecca et al.,Abstract C30: Phase 1/2 study of the vascular disrupting agent (VDA) Plinabulin (NPI-2358 ) combined with docetaxel in patients with non-small cell lung cancer (NSCLC),Molecular Cancer Therapeutics,2009年12月10日,Vol. 8, No.12 Suppl.,C30,DOI: 10.1158/1535-7163.TARG-09-C30
Mazza, Valentina et al.,Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib,Application of Clinical Genetics,2017年07月26日,Vol.10,49-56,DOI: 10.2147/TACG.S103471
日本内科学会雑誌,2017年,Vol.106,No.3,p.534-539

Also Published As

Publication number Publication date
KR20210015875A (ko) 2021-02-10
AU2019278886B2 (en) 2025-03-20
JP2021525768A (ja) 2021-09-27
US20210161888A1 (en) 2021-06-03
CA3101612A1 (en) 2019-12-05
DK3801524T3 (da) 2026-02-02
MX420412B (es) 2025-02-10
WO2019232257A1 (en) 2019-12-05
AU2019278886A1 (en) 2020-12-24
CN112543636A (zh) 2021-03-23
MX2020012799A (es) 2021-03-25
KR102790127B1 (ko) 2025-04-03
ES3060133T3 (en) 2026-03-25
EP3801524B1 (en) 2025-11-05
EP3801524A4 (en) 2022-03-02
US20250375440A1 (en) 2025-12-11
EP3801524A1 (en) 2021-04-14
CN112543636B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
US20250375440A1 (en) Composition and method of treating cancer associated with egfr mutation
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
JP2022520079A (ja) Tno155及びkrasg12c阻害剤を含む医薬組合せ
EP3010505A1 (en) Pharmaceutical combinations
US20230293464A1 (en) Treatment of pancreatic ductal adenocarcinoma with mirdametinib
EP2925366B1 (en) Pharmaceutical combinations
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
JP2025509278A (ja) 小細胞肺癌を治療する方法
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
EP4719416A1 (en) Oncology combination therapy and methods of use
WO2024081948A1 (en) Combination for use in treating cancers
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
HK40038993A (en) Composition and method of treating cancer associated with egfr mutation
US20240307392A1 (en) Erk1/2 and egfr inhibitors combination therapy
CN115120596A (zh) 一种喹唑啉化合物及药物组合物的应用
JP2026509292A (ja) 腫瘍学的併用療法及びその使用方法
HK1215789B (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A603 Late request for extension of time limit during examination

Free format text: JAPANESE INTERMEDIATE CODE: A603

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240605

R150 Certificate of patent or registration of utility model

Ref document number: 7500438

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150